Bandingkan Harga & Kinerja PP London Sumatra Indonesia Tbk. (LSIP) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan PP London Sumatra Indonesia Tbk. dan Organon Pharma Indonesia Tbk.: PP London Sumatra Indonesia Tbk. diperdagangkan di Rp1.700 (kapitalisasi pasar 11,49 T, volume 24 jam 15,99 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: PP London Sumatra Indonesia Tbk. jauh lebih besar — sekitar 110,1× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| LSIP | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 11,49 T | 104,4 M |
Volume | 15,99 jt | — |
Lot | 159,9 rb | — |
Perputaran | 27,34 M | — |
Harga Rata-rata | 1.710,03 | — |
Nilai Transaksi | 27,34 M | — |
Harga Ekuilibrium Indikatif | 1.700 | — |
Volume Ekuilibrium Indikatif | 2,92 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang PP London Sumatra Indonesia Tbk.
PT Perusahaan Perkebunan London Sumatera Tbk abbreviated as Lonsum, was established in teh Republic of Indonesia based on Notarial Deed No. 93 of Raden Kadiman dated December 18, 1962 and amended by Notarial Deed No. 20 dated September 9, 1963. Based on Notarial Deed No. 18 of Pahala Sutrisno Amijoyo Tampubolon, S.H., M.Kn., dated May 24, 2013, the Company's shareholders approved the change of the Company's status from Foreign Capital Investment (PMA) company to Domestic Capital Investment (PMDN) company.
Selengkapnya di halaman LSIP →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
